Encapsulation,<i>In Vitro</i>Characterization, and<i>In Vivo</i>Biocompatibility of Sertoli Cells in Alginate-Based Microcapsules

Luca, Giovanni; Calvitti, Mario; Nastruzzi, Claudio; Bilancetti, Luca; Becchetti, Ennio; Angeletti, G; Mancuso, Francesca; Calafiore, Riccardo

doi:10.1089/ten.2006.0137

Cited by 59 publications

(55 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ions belonging to the second group of the Mendeleev's periodic table share the ability to ligate alginate. Barium alginate microcapsules are mechanically stable and easy to obtain, with a procedure that is substantially independent of the type of cells to be encapsulated [101,110].…”

Section: The Encapsulation Chancementioning

confidence: 99%

Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy

Chiappalupi

Salvadori

Luca

et al. 2017

JFMK

Self Cite

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD) is a lethal X-linked pathology due to lack of dystrophin and characterized by progressive muscle degeneration, impaired locomotion and premature death. The chronic presence of inflammatory cells, fibrosis and fat deposition are hallmarks of DMD muscle tissue. Many different therapeutic approaches to DMD have been tested, including cell-based and gene-based approaches, exon skipping, induction of expression of the dystrophin paralogue, utrophin, and, most recently the application of the CASPR/Cas9 genome editing system. However, corticosteroid treatment remains the gold standard therapy, even if corticosteroids have shown multiple undesirable side effects. Sertoli cells (SeC) have long been known for their ability to produce immunomodulatory and trophic factors, and have been used in a plethora of experimental models of disease. Recently, microencapsulated porcine SeC (MC-SeC) injected intraperitoneally in dystrophic mice produced morphological and functional benefits in muscles thanks to their release into the circulation of anti-inflammatory factors and heregulin β1, a known inducer of utrophin expression, thus opening a new avenue in the treatment of DMD. In order to stress the potentiality of the use of MC-SeC in the treatment of DMD, here, we examine the principal therapeutic approaches to DMD, and the properties of SeC (either nude or encapsulated into alginate-based microcapsules) and their preclinical and clinical use. Finally, we discuss the potential and future development of this latter approach.Keywords: Duchenne muscular dystrophy; therapeutic approaches; Sertoli cell; muscle inflammation; myopathies; encapsulation; biomaterials Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy. Muscular dystrophies are a group of inherited muscle diseases characterized by mutations in specific genes and resulting in muscle degeneration, impaired locomotion and premature death [1,2]. DMD is an X-linked recessive pathology caused by mutations in the dystrophin gene (DMD) usually resulting in the complete absence of this protein. Dystrophin is an essential component of the dystrophin-associated protein complex (DAPC) at the sarcolemma, a complex that ensures the structural and functional integrity of the myofibers during contraction representing a mechanical link between the intracellular cytoskeleton and the extracellular matrix. Absence of dystrophin or other components of the DAPC compromises the integrity of the DAPC itself leading to a susceptibility of myofibers to degeneration

show abstract

Section: The Encapsulation Chancementioning

confidence: 99%

Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy

Chiappalupi

Salvadori

Luca

et al. 2017

JFMK

Self Cite

View full text Add to dashboard Cite

show abstract

“…SCs were isolated from the testes of neonatal pre-pubertal ''Large-White" pigs, aged 7-15 days, according to previously reported methods and as modified in our laboratory [12]. Briefly, decapsulated testicular tissue was minced and then digested with trypsin (2 mg ml À1 ) and DNAse I (Sigma) to obtain a clean fraction of seminiferous tubules devoid of other testicular cells such as Leydig cells and peritubular cells.…”

Section: Isolation Of Scsmentioning

confidence: 99%

“…After washing the Tris off, the SCs were cultured under the same conditions, in 75 cm 2 cell culture flasks. After isolation, purified SC monolayers were identified by anti-Mullerian inhibiting substance (MIS) immunostaining, according to previous reports [12]. Cell viability was assessed, before and after encapsulation, by double staining with PI and Calcein-AM according to the manufacturer's instructions.…”

Section: Isolation Of Scsmentioning

confidence: 99%

Production and characterization of engineered alginate-based microparticles containing ECM powder for cell/tissue engineering applications

et al. 2011

Self Cite

View full text Add to dashboard Cite

“…Highly monodisperse hydrogel microbeads have many important applications in pharmacy (Nortier et al 1995), food coatings (Sanguansri et al 2006) and biomedical industries such as cell encapsulation (Jen et al 1996;Luca et al 2007) and drug delivery systems (Graham and Mcneill 1984). In cell encapsulation for tissue engineering and cell-based beads array systems, micro-sized monodisperse hydrogel beads are in demand since they facilitate handling and allow rapid exchange of nutrients into and waste out of these beads.…”

Section: Introductionmentioning

confidence: 99%

Three-dimensional axisymmetric flow-focusing device using stereolithography

Morimoto

Tan

Takeuchi

2008

Biomed Microdevices

View full text Add to dashboard Cite

This paper describes a three-dimensional microfluidic axisymmetric flow-focusing device (AFFD) fabricated using stereolithography. Using this method, we can fabricate AFFDs rapidly and automatically without cumbersome alignment needed in conventional methods. The AFFDs are able to be fabricated reproducibly with a micro-sized orifice of diameter around 250 mum. Using this device, we are able to produce monodisperse water-in-oil (W/O) droplets with a coefficient of variation (CV) of less than 4.5%, W/O droplets with encapsulated microbes (CV < 4.9%) and oil-in-water (O/W) droplets (CV < 3.2%) without any surface modifications. The diameter of these droplets range from 54 to 244 mum with respect to the flow rate ratio of the fluids used; these results are in good agreement with theoretical behavior. For applications of the AFFD, we demonstrate that these devices can be used to produce double emulsions and monodisperse hydrogel beads.

show abstract

Encapsulation,In VitroCharacterization, andIn VivoBiocompatibility of Sertoli Cells in Alginate-Based Microcapsules

Cited by 59 publications

References 23 publications

Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy

Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy

Production and characterization of engineered alginate-based microparticles containing ECM powder for cell/tissue engineering applications

Three-dimensional axisymmetric flow-focusing device using stereolithography

Contact Info

Product

Resources

About